ES
MCID: EWN003
MIFTS: 74

Ewing Sarcoma (ES)

Categories: Bone diseases, Cancer diseases, Eye diseases, Genetic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Ewing Sarcoma

MalaCards integrated aliases for Ewing Sarcoma:

Name: Ewing Sarcoma 58 12 54 26 60 76 38 13 15 17
Neuroepithelioma 58 77 54 60 56 74
Ewing's Sarcoma 77 54 26 30 6
Ewing's Tumor 12 54 26 76
Ewings Sarcoma 12 56 74
Eye Disease 12 15 17
Localized Peripheral Primitive Neuroectodermal Tumor 12 74
Ewings Sarcoma-Primitive Neuroectodermal Tumor 12 74
Peripheral Primitive Neuroectodermal Tumor 12 60
Peripheral Neuroepithelioma 76 56
Sarcoma, Ewing's 54 41
Askin Tumor 76 45
Ewing Tumor 54 26
Es 58 76
Localized Ewing's Sarcoma/peripheral Primitive Neuroectodermal Tumor 12
Extraosseous Ewings Sarcoma-Primitive Neuroepithelial Tumor 74
Ewing's Sarcoma/peripheral Primitive Neuroectodermal Tumor 12
Neuroectodermal Tumors, Primitive, Peripheral 45
Neuroectodermal Tumor, Primitive 74
Pnet of Thoracopulmonary Region 12
Primitive Neuroectodermal Tumor 76
Ewing's Family Localized Tumor 12
Ewing Sarcoma Family of Tumors 76
Neuroepithelioma, Peripheral 74
Localized Ewing's Sarcoma 12
Tumor of the Ewing Family 26
Extraosseous Ewing Tumor 76
Localized Ewing Sarcoma 12
Localized Ewing's Tumor 12
Ewing Family of Tumors 26
Pnet of the Chest Wall 76
Peripheral Pnet 60
Disorder of Eye 74
Sarcoma, Ewing 45
Askin's Tumor 74
Eye Diseases 45
Ppnet 60
Pnet 76
Esft 76
Pne 76

Characteristics:

Orphanet epidemiological data:

60
ewing sarcoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe); Age of onset: Childhood;
neuroepithelioma
Inheritance: Not applicable; Age of onset: Childhood;

HPO:

33
ewing sarcoma:
Inheritance somatic mutation


Classifications:



Summaries for Ewing Sarcoma

Genetics Home Reference : 26 Ewing sarcoma is a cancerous tumor that occurs in bones or soft tissues, such as cartilage or nerves. There are several types of Ewing sarcoma, including Ewing sarcoma of bone, extraosseous Ewing sarcoma, peripheral primitive neuroectodermal tumor (pPNET), and Askin tumor. These tumors are considered to be related because they have similar genetic causes. These types of Ewing sarcoma can be distinguished from one another by the tissue in which the tumor develops. Approximately 87 percent of Ewing sarcomas are Ewing sarcoma of bone, which is a bone tumor that usually occurs in the thigh bones (femurs), pelvis, ribs, or shoulder blades. Extraosseous (or extraskeletal) Ewing sarcoma describes tumors in the soft tissues around bones, such as cartilage. pPNETs occur in nerve tissue and can be found in many parts of the body. A type of pPNET found in the chest is called Askin tumor.

MalaCards based summary : Ewing Sarcoma, also known as neuroepithelioma, is related to extraskeletal ewing sarcoma and cerebral primitive neuroectodermal tumor, and has symptoms including fever, visual disturbance and eye manifestations. An important gene associated with Ewing Sarcoma is EWSR1 (EWS RNA Binding Protein 1), and among its related pathways/superpathways are Transcriptional misregulation in cancer and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Melphalan and Zoledronic Acid have been mentioned in the context of this disorder. Affiliated tissues include bone, eye and lung, and related phenotypes are peripheral primitive neuroectodermal neoplasm and seizures

Disease Ontology : 12 A bone cancer that has_material_basis in neural crest cells derives from undeveloped, undifferentiated neuroectoderm.

NIH Rare Diseases : 54 Ewing sarcoma is a malignant (cancerous) bone tumor that affects children. It can occur any time during childhood and young adulthood, but usually develops during puberty, when bones are growing rapidly. The tumor may arise anywhere in the body, usually in the long bones of the arms and legs, the pelvis, or the chest. It may also develop in the skull or the flat bones of the trunk. There are few symptoms. The most common is pain and occasionally swelling at the site of the tumor. Fever may also be present. The tumor often spreads (metastasis) to the lungs and other bones. The cause of Ewing sarcoma is unknown. Most cases are thought to occur randomly and many involved a reciprocal translocation between chromosomes 11 and 22. Treatment depends upon a number of factors, but may include chemotherapy, radiation and/or surgical interventions.

OMIM : 58 The Ewing sarcoma family of tumors (primitive neuroectodermal tumors; PNET) comprise morphologically heterogeneous tumors that are characterized by nonrandom chromosomal translocations involving the EWS gene on chromosome 22q12 and one of several members of the ETS family of transcription factors. The tumors include Ewing sarcoma, peripheral neuroepithelioma, and Askin tumor. In approximately 90% of cases of ESFT, the FLI1 gene (193067) on chromosome 11 is the fusion partner of EWS; in approximately 10%, the EWS fusion partner is the ERG gene (165080) on chromosome 22. Many other ETS family members have been identified as fusion partners of EWS, but these cases are rare (Khoury, 2005). (612219)

UniProtKB/Swiss-Prot : 76 Ewing sarcoma: A highly malignant, metastatic, primitive small round cell tumor of bone and soft tissue that affects children and adolescents. It belongs to the Ewing sarcoma family of tumors, a group of morphologically heterogeneous neoplasms that share the same cytogenetic features. They are considered neural tumors derived from cells of the neural crest. Ewing sarcoma represents the less differentiated form of the tumors.

Wikipedia : 77 Ewing''s sarcoma is a type of cancer that forms in bone or soft tissue. Symptoms may include swelling... more...

Related Diseases for Ewing Sarcoma

Diseases related to Ewing Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 785)
# Related Disease Score Top Affiliating Genes
1 extraskeletal ewing sarcoma 35.0 CD99 ENO2 ERG EWSR1 FLI1 FUS
2 cerebral primitive neuroectodermal tumor 34.8 ENO2 MYC MYCN
3 primitive neuroectodermal tumor of the cervix uteri 34.8 ENO2 PTPRC
4 intracranial primitive neuroectodermal tumor 34.7 CD99 ENO2
5 sarcoma 33.5 ERG ETV1 EWSR1 FLI1 FUS KIT
6 askin's tumor 33.4 ENO2 EWSR1 MYC MYCN
7 rhabdoid tumor predisposition syndrome 1 33.3 IGF1R PTPRC WT1
8 bone ewing's sarcoma 33.2 CD99 ENO2 EWSR1 MYC MYCN PTPRC
9 extraosseous ewing's sarcoma 33.1 CD99 ENO2 ETV4 EWSR1 MYCN MYOG
10 ewing's family of tumors 32.3 EWSR1 FLI1 KIT
11 rhabdomyosarcoma 31.6 ENO2 EWSR1 IGF1R MYCN MYOG PTPRC
12 kidney rhabdoid cancer 31.4 CD99 ENO2 EWSR1 PTPRC WT1
13 desmoplastic small round cell tumor 31.3 ENO2 EWSR1 WT1
14 cauda equina neoplasm 31.3 ENO2 EWSR1 WT1
15 leukemia, acute myeloid 31.3 KIT MYC NCAM1 PTPRC WT1
16 small cell osteogenic sarcoma 31.2 ENO2 EWSR1
17 rhabdoid cancer 31.2 ENO2 EWSR1 WT1
18 histiocytoma 31.2 EWSR1 FUS KIT PTPRC
19 small cell carcinoma 31.2 ENO2 KIT NCAM1 PTPRC
20 olfactory neuroblastoma 31.1 ENO2 EWSR1 PTPRC
21 embryonal rhabdomyosarcoma 31.1 EWSR1 MYCN MYOG
22 myeloid sarcoma 31.1 KIT NCAM1 PTPRC
23 chondrosarcoma, extraskeletal myxoid 31.0 ENO2 EWSR1 FUS WT1
24 extraosseous chondrosarcoma 31.0 ENO2 EWSR1 FUS
25 teratoma 31.0 CD99 ENO2 KIT POU5F1
26 rhabdomyosarcoma 2 31.0 ENO2 EWSR1 IGF1R MYCN MYOG WT1
27 bladder sarcoma 31.0 CD99 EWSR1
28 clear cell sarcoma 30.9 ENO2 EWSR1 FUS KIT WT1
29 medullomyoblastoma 30.9 ENO2 MYC MYCN MYOG
30 heart sarcoma 30.9 ENO2 KIT WT1
31 gastrointestinal stromal tumor 30.9 ENO2 ETV1 KIT NCAM1
32 wilms tumor 1 30.9 ENO2 EWSR1 IGF1R MYC MYCN MYOG
33 malignant teratoma 30.8 ENO2 POU5F1
34 angiosarcoma 30.8 FLI1 KIT MYC
35 merkel cell carcinoma 30.8 ENO2 KIT NCAM1
36 vulvar sarcoma 30.7 EWSR1 PTPRC
37 medulloblastoma 30.6 ENO2 IGF1R MYC MYCN NCAM1
38 small cell cancer of the lung 30.4 ENO2 KIT MYC MYCN NCAM1
39 fish-eye disease 12.5
40 aland island eye disease 12.5
41 supratentorial primitive neuroectodermal tumors, childhood 12.4
42 primitive neuroectodermal tumor of the corpus uteri 12.4
43 extraosseous ewings sarcoma-primitive neuroepithelial tumor 12.3
44 soft tissue peripheral neuroepithelioma 12.2
45 bone peripheral neuroepithelioma 12.2
46 dissociative seizures 12.1
47 pancreatic neuroendocrine tumor 11.8
48 pineoblastoma 11.8
49 spinal cord primitive neuroectodermal neoplasm 11.7
50 cerebellopontine angle primitive neuroectodermal 11.7

Graphical network of the top 20 diseases related to Ewing Sarcoma:



Diseases related to Ewing Sarcoma

Symptoms & Phenotypes for Ewing Sarcoma

Human phenotypes related to Ewing Sarcoma:

60 33 (show all 38)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 peripheral primitive neuroectodermal neoplasm 60 33 obligate (100%) Obligate (100%) HP:0030067
2 seizures 60 33 occasional (7.5%) Occasional (29-5%) HP:0001250
3 nausea and vomiting 60 33 occasional (7.5%) Occasional (29-5%) HP:0002017
4 ascites 60 33 occasional (7.5%) Occasional (29-5%) HP:0001541
5 anemia 60 33 occasional (7.5%) Occasional (29-5%) HP:0001903
6 abnormal bleeding 60 33 occasional (7.5%) Occasional (29-5%) HP:0001892
7 pruritus 60 33 occasional (7.5%) Occasional (29-5%) HP:0000989
8 weight loss 60 33 occasional (7.5%) Occasional (29-5%) HP:0001824
9 jaundice 60 33 occasional (7.5%) Occasional (29-5%) HP:0000952
10 back pain 60 33 occasional (7.5%) Occasional (29-5%) HP:0003418
11 pancreatitis 60 33 occasional (7.5%) Occasional (29-5%) HP:0001733
12 anorexia 60 33 occasional (7.5%) Occasional (29-5%) HP:0002039
13 vertigo 60 33 occasional (7.5%) Occasional (29-5%) HP:0002321
14 headache 60 33 occasional (7.5%) Occasional (29-5%) HP:0002315
15 episodic abdominal pain 60 33 occasional (7.5%) Occasional (29-5%) HP:0002574
16 hyporeflexia 60 33 occasional (7.5%) Occasional (29-5%) HP:0001265
17 ovarian neoplasm 60 33 occasional (7.5%) Occasional (29-5%) HP:0100615
18 neoplasm of the pancreas 60 33 occasional (7.5%) Occasional (29-5%) HP:0002894
19 abdominal distention 60 33 occasional (7.5%) Occasional (29-5%) HP:0003270
20 torticollis 60 33 occasional (7.5%) Occasional (29-5%) HP:0000473
21 lower limb muscle weakness 60 33 occasional (7.5%) Occasional (29-5%) HP:0007340
22 spinal cord tumor 60 33 occasional (7.5%) Occasional (29-5%) HP:0010302
23 metrorrhagia 60 33 occasional (7.5%) Occasional (29-5%) HP:0100608
24 uterine neoplasm 60 33 occasional (7.5%) Occasional (29-5%) HP:0010784
25 sensory impairment 60 33 occasional (7.5%) Occasional (29-5%) HP:0003474
26 elevated carcinoma antigen 125 level 60 33 occasional (7.5%) Occasional (29-5%) HP:0031030
27 abnormality of the scalp 60 33 occasional (7.5%) Occasional (29-5%) HP:0001965
28 upper limb pain 60 33 occasional (7.5%) Occasional (29-5%) HP:0012513
29 brain neoplasm 60 33 occasional (7.5%) Occasional (29-5%) HP:0030692
30 pelvic mass 60 33 occasional (7.5%) Occasional (29-5%) HP:0031501
31 abnormality of the thoracic spine 60 33 occasional (7.5%) Occasional (29-5%) HP:0100711
32 precocious puberty 60 33 very rare (1%) Very rare (<4-1%) HP:0000826
33 increased lactate dehydrogenase activity 60 33 very rare (1%) Very rare (<4-1%) HP:0025435
34 proptosis 60 33 very rare (1%) Very rare (<4-1%) HP:0000520
35 elevated alpha-fetoprotein 60 33 very rare (1%) Very rare (<4-1%) HP:0006254
36 abnormality of the superior cerebellar peduncle 60 33 very rare (1%) Very rare (<4-1%) HP:0011932
37 neoplasm of the scrotum 60 33 very rare (1%) Very rare (<4-1%) HP:0100849
38 ewing sarcoma 33 HP:0012254

Clinical features from OMIM:

612219

UMLS symptoms related to Ewing Sarcoma:


fever, visual disturbance, eye manifestations, pathological conditions, signs and symptoms, redness or discharge of eye, pain in or around eye, lid retraction

GenomeRNAi Phenotypes related to Ewing Sarcoma according to GeneCards Suite gene sharing:

27 (show all 21)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.78 XAGE1A XAGE1B
2 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.78 IGF1R
3 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.78 XAGE1A XAGE1B
4 Increased shRNA abundance (Z-score > 2) GR00366-A-12 9.78 XAGE1A XAGE1B
5 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.78 CD99
6 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.78 IGF1R
7 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.78 CD99
8 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.78 XAGE1A XAGE1B
9 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.78 IGF1R
10 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.78 IGF1R
11 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.78 CD99
12 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.78 CD99 IGF1R XAGE1A XAGE1B
13 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.78 IGF1R
14 Increased shRNA abundance (Z-score > 2) GR00366-A-4 9.78 CD99
15 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.78 IGF1R
16 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.78 IGF1R
17 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.78 XAGE1A XAGE1B
18 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.78 IGF1R
19 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.78 CD99
20 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.78 IGF1R
21 Increased shRNA abundance (Z-score > 2) GR00366-A-96 9.78 CD99

MGI Mouse Phenotypes related to Ewing Sarcoma:

47 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.29 ENO2 ERG ETV1 FLI1 IGF1R KIT
2 behavior/neurological MP:0005386 10.22 ENO2 ETV1 ETV4 IGF1R KIT MYC
3 mortality/aging MP:0010768 10.22 ERG ETV1 ETV4 FLI1 IGF1R KIT
4 growth/size/body region MP:0005378 10.2 ENO2 ERG ETV1 FLI1 IGF1R KIT
5 embryo MP:0005380 10.19 ERG ETV4 FLI1 IGF1R KIT MYC
6 endocrine/exocrine gland MP:0005379 10.13 ERG ETV4 FLI1 IGF1R KIT MYC
7 liver/biliary system MP:0005370 10.03 FLI1 IGF1R KIT MYC MYCN POU5F1
8 nervous system MP:0003631 10.03 ENO2 ERG ETV1 ETV4 FLI1 IGF1R
9 muscle MP:0005369 10.02 ETV1 ETV4 FLI1 IGF1R KIT MYC
10 neoplasm MP:0002006 9.92 ERG ETV4 FLI1 IGF1R KIT MYC
11 no phenotypic analysis MP:0003012 9.7 ETV4 KIT MYC MYCN MYOG PTPRC
12 normal MP:0002873 9.61 ERG ETV1 KIT MYC MYCN MYOG
13 respiratory system MP:0005388 9.23 ENO2 ERG IGF1R KIT MYCN MYOG

Drugs & Therapeutics for Ewing Sarcoma

Drugs for Ewing Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 279)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Melphalan Approved Phase 3,Phase 2,Phase 1,Not Applicable 148-82-3 460612 4053
2
Zoledronic Acid Approved Phase 3,Phase 1 118072-93-8 68740
3
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
4
Ifosfamide Approved Phase 3,Phase 2,Phase 1,Not Applicable 3778-73-2 3690
5
Cyclophosphamide Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
6
Etoposide Approved Phase 3,Phase 1,Phase 2,Not Applicable 33419-42-0 36462
7
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
8
Dactinomycin Approved, Investigational Phase 3,Phase 2,Not Applicable 50-76-0 457193 2019
9
Mesna Approved, Investigational Phase 3,Phase 1,Phase 2 3375-50-6 598
10
Cobalt Approved, Experimental Phase 3,Phase 2 7440-48-4 104729
11
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
12
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 51-75-2 4033
13
Carboplatin Approved Phase 3,Phase 1,Phase 2,Not Applicable 41575-94-4 10339178 38904 498142
14
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
15
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
16
Sargramostim Approved, Investigational Phase 3,Phase 2,Phase 1 123774-72-1, 83869-56-1
17
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
18
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
19
Modafinil Approved, Investigational Phase 3,Phase 2,Phase 1 68693-11-8 4236
20
Temozolomide Approved, Investigational Phase 3,Phase 1,Phase 2 85622-93-1 5394
21
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 119413-54-6, 123948-87-8 60700
22 Cranberry Approved, Investigational Phase 3
23 Grape Approved Phase 3
24
Histamine Approved, Investigational Phase 3 51-45-6 774
25
Cyproheptadine Approved Phase 3 129-03-3 2913
26
Treosulfan Investigational Phase 3 299-75-2 9296
27
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1,Not Applicable 31703
28 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
29
Camptothecin Experimental Phase 3,Phase 1,Phase 2 7689-03-4
30
Emodepside Investigational, Vet_approved Phase 3 155030-63-0
31 Deslorelin Investigational, Vet_approved Phase 2, Phase 3 57773-65-6
32 Immunosuppressive Agents Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
33 Diphosphonates Phase 3
34 Immunologic Factors Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
35 Antineoplastic Agents, Alkylating Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
36 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Bone Density Conservation Agents Phase 3,Phase 1
38 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
39 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40
Isophosphamide mustard Phase 3,Phase 2,Phase 1,Not Applicable 0
41 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
42 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
44 Etoposide phosphate Phase 3,Phase 1,Phase 2,Not Applicable
45 Antirheumatic Agents Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
46 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
47 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
48 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1,Not Applicable
49 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
50 topoisomerase I inhibitors Phase 3,Phase 1,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 272)
# Name Status NCT ID Phase Drugs
1 Study in Localized and Disseminated Ewing Sarcoma Unknown status NCT00987636 Phase 3 Zoledronic acid;Busulfan;Treosulfan
2 Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma Unknown status NCT00002516 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
3 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status NCT00020566 Phase 3 busulfan;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;vincristine sulfate
4 Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma Completed NCT02063022 Phase 3 Standard treatment (as per protocol ISG SSG III);Intensified chemotherapy
5 Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor Completed NCT00006734 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
6 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
7 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
8 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
9 Vigil + Irinotecan and Temozolomide in Ewing's Sarcoma Recruiting NCT03495921 Phase 3 Irinotecan;Temozolomide
10 Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Active, not recruiting NCT01231906 Phase 3 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Topotecan Hydrochloride;Vincristine Sulfate
11 Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma Active, not recruiting NCT02306161 Phase 3 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Vincristine Sulfate
12 Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer Active, not recruiting NCT02856048 Phase 2, Phase 3 Triptorelin (GnRHa) + Chemotherapy
13 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
14 Post-operative Radiotherapy in Poor Responders Ewing's Sarcoma Patients Withdrawn NCT01734863 Phase 3
15 Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma Withdrawn NCT00334867 Phase 3 cyclophosphamide;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate
16 Hematopoietic Stem Cell Transplantation From Human Leukocyte Antigen (HLA) Compatible Donor in Ewing Sarcomas and Soft Tissues Sarcomas Unknown status NCT00998361 Phase 2
17 Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse Unknown status NCT00180947 Phase 2 Vinorelbine, cyclofosfamide
18 Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors Unknown status NCT00179816 Phase 1, Phase 2 High-Dose Chemotherapy with Tandem PBSC Rescue.
19 Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Unknown status NCT00084695 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;melphalan;methylprednisolone
20 Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults Completed NCT01696669 Phase 2 Chemotherapy
21 Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma Completed NCT01583543 Phase 2 Olaparib
22 Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma Completed NCT02546544 Phase 2 Linsitinib
23 Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors Completed NCT00560235 Phase 1, Phase 2 CP-751,871
24 Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors Completed NCT00061893 Phase 2 celecoxib;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vinblastine sulfate;vincristine sulfate;MESNA;Filgrastim
25 Aerosol L9-NC and Temozolomide in Ewing's Sarcoma Completed NCT00492141 Phase 1, Phase 2 Temozolomide;L9-NC
26 Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma Completed NCT00470275 Phase 2 cytarabine
27 Irinotecan in Treating Patients With Newly Diagnosed Ewing's Sarcoma Completed NCT00276692 Phase 2 irinotecan hydrochloride
28 Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma Completed NCT00516295 Phase 2 topotecan hydrochloride;vincristine sulfate;cyclophosphamide
29 New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma Completed NCT00001335 Phase 2 ADR-529;Topotecan;G-CSF
30 Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma Completed NCT00003667 Phase 2 cyclophosphamide;dexrazoxane hydrochloride;disaccharide tripeptide glycerol dipalmitoyl;doxorubicin hydrochloride;vincristine sulfate
31 Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma Completed NCT01492673 Phase 2 Cyclophosphamide, Topotecan, and Bevacizumab
32 Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma Completed NCT00073983 Phase 2 docetaxel;gemcitabine hydrochloride
33 Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor Completed NCT00002643 Phase 2 amifostine trihydrate;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate
34 Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Ewing's Sarcoma or Rhabdomyosarcoma That Has Spread to the Bone Completed NCT00006234 Phase 1, Phase 2
35 Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor Completed NCT00055952 Phase 2 exatecan mesylate
36 Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors Completed NCT00357396 Phase 2 busulfan;melphalan;thiotepa
37 Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy Completed NCT01222767 Phase 2 Zalypsis
38 Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer Completed NCT00002466 Phase 2 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
39 Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor Completed NCT00062205 Phase 2 imatinib mesylate
40 Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors Completed NCT00070109 Phase 2 trabectedin
41 Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma Completed NCT00923351 Phase 1, Phase 2 Tumor Purged/CD25 Depleted Lymphocytes;rhIL-7
42 A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma Completed NCT00668148 Phase 2
43 A Study of R1507 in Participants With Recurrent or Refractory Sarcoma Completed NCT00642941 Phase 2 RG1507
44 A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas Completed NCT00001566 Phase 2 indinavir sulfate
45 A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas Completed NCT00001564 Phase 2 EF-1 Peptide;EF-2 Peptide;PXFK Peptide;E7 Peptide;IL-2;IL-4;GM-CSF;CD40 Ligand
46 Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors Completed NCT01962103 Phase 1, Phase 2 nab-paclitaxel;nab-paclitaxel
47 A Study of Pemetrexed in Children With Recurrent Cancer Completed NCT00520936 Phase 2 pemetrexed
48 Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas Completed NCT00165139 Phase 2 Vincristine;Cyclophosphamide;Adriamycin;Etoposide (VP-16);Cisplatin;Carboplatin;Melphalan;Ifosfamide;G-CSF (granulocyte-colony stimulating factor);Mesna
49 A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone Completed NCT01288573 Phase 1, Phase 2 plerixafor;plerixafor;plerixafor
50 Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure Completed NCT01136499 Phase 2 LBH589 (Panobinostat®)

Search NIH Clinical Center for Ewing Sarcoma

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: eye diseases

Genetic Tests for Ewing Sarcoma

Genetic tests related to Ewing Sarcoma:

# Genetic test Affiliating Genes
1 Ewing's Sarcoma 30 EWSR1

Anatomical Context for Ewing Sarcoma

MalaCards organs/tissues related to Ewing Sarcoma:

42
Bone, Eye, Lung, Brain, T Cells, Kidney, Thyroid

Publications for Ewing Sarcoma

Articles related to Ewing Sarcoma:

(show top 50) (show all 1621)
# Title Authors Year
1
Treatment Outcomes of Pediatric Patients With Ewing Sarcoma in a War-Torn Nation: A Single-Institute Experience From Iraq. ( 30707662 )
2019
2
Bone Sarcoma With EWSR1-NFATC2 Fusion: Sarcoma With Varied Morphology and Amplification of Fusion Gene Distinct From Ewing Sarcoma. ( 30714449 )
2019
3
NKX2.2 immunohistochemistry in the distinction of Ewing sarcoma from cytomorphologic mimics: Diagnostic utility and pitfalls-Comment on Russell-Goldman et al. ( 30720925 )
2019
4
Bone marrow biopsy in the initial staging of Ewing sarcoma: Experience from a single institution. ( 30724024 )
2019
5
Adamantinoma-Like Ewing Sarcoma of the Thyroid: A Case Report and Review of the Literature. ( 30734898 )
2019
6
Targeting the CALCB/RAMP1 axis inhibits growth of Ewing sarcoma. ( 30741933 )
2019
7
Getting control during follow-up visits: the views and experiences of parents on tumor surveillance after their children have completed therapy for rhabdomyosarcoma or Ewing sarcoma. ( 30747278 )
2019
8
Primary cutaneous Ewing sarcoma in a young girl. ( 30761992 )
2019
9
SCMCIE94: an intensified pilot treatment protocol known to be associated with cure in CD 56-negative non-pelvic isolated Ewing sarcoma (EWS) is also associated with no early relapses in non-metastatic extremity EWS. ( 30770960 )
2019
10
Outcomes in different age groups with primary Ewing sarcoma of the spine: a systematic review of the literature. ( 30771777 )
2019
11
The relation of radiological tumor volume response to histological response and outcome in patients with localized Ewing Sarcoma. ( 30790456 )
2019
12
A nomogram to predict prognosis in Ewing sarcoma of bone. ( 30815343 )
2019
13
Getting away with phase transition: NPM1-mutated bone myeloid sarcoma mimicking Ewing sarcoma. ( 30879096 )
2019
14
EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells. ( 30879952 )
2019
15
Correction: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. ( 30880335 )
2019
16
Radiation Treatment for Ewing Sarcoma Family of Tumors in Adult Patients: A Single Institution's Experience Over 40 Years. ( 30883389 )
2019
17
Multimodal Treatment in Pelvic Ewing Sarcoma: A Prognostic Factor Analysis. ( 30888673 )
2019
18
Predicting Ewing Sarcoma Treatment Outcome Using Infrared Spectroscopy and Machine Learning. ( 30893786 )
2019
19
DNA methylation profiling distinguishes Ewing-like sarcoma with EWSR1-NFATc2 fusion from Ewing sarcoma. ( 30895378 )
2019
20
Gastrointestinal: Multi-modality imaging of extraskeletal Ewing sarcoma of the stomach. ( 30912185 )
2019
21
Whole-body MRI vs bone scintigraphy in the staging of Ewing sarcoma of bone: a 12-year single-institution review. ( 30915559 )
2019
22
Ewing Sarcoma in Nepal Treated With Combined Chemotherapy and Definitive Radiotherapy. ( 30917070 )
2019
23
Targeting the IGF1R/PI3K/AKT Pathway Sensitizes Ewing Sarcoma to BET Bromodomain Inhibitors. ( 30926641 )
2019
24
The prognostic signature of the somatic mutations in Ewing sarcoma: from a network view. ( 30927420 )
2019
25
Maintenance treatment with trofosfamide in patients with primary bone ewing sarcoma - single center experience. ( 30954980 )
2019
26
High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma. ( 30979745 )
2019
27
Pathfinders in oncology from the end of the 19th century to the first description of Ewing sarcoma. ( 30985918 )
2019
28
Management of recurrent Ewing sarcoma: challenges and approaches. ( 30988632 )
2019
29
Primary cutaneous Ewing sarcoma in a young girl. ( 30998216 )
2019
30
Are EWSR1-FLI-positive cell lines from patients with other diagnoses than Ewing sarcoma really Ewing sarcoma cell lines? ( 31006967 )
2019
31
18F-FDG PET-CT versus MRI for detection of skeletal metastasis in Ewing sarcoma. ( 31016339 )
2019
32
Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis. ( 31025088 )
2019
33
Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children's Oncology Group (COG) New Agents for Ewing Sarcoma Task Force. ( 31031965 )
2019
34
EWSR1-FLI1 activation of the cancer/testis antigen FATE1 promotes Ewing sarcoma survival. ( 31036566 )
2019
35
Early versus delayed administration of granulocyte-colony stimulating factor following chemotherapy in pediatric patients with Ewing sarcoma. ( 31042138 )
2019
36
β3-Adrenoreceptor Activity Limits Apigenin Efficacy in Ewing Sarcoma Cells: A Dual Approach to Prevent Cell Survival. ( 31052299 )
2019
37
The promoter associated non-coding RNA pncCCND1_B assembles a protein-RNA complex to regulate cyclin D1 transcription in Ewing sarcoma. ( 31072811 )
2019
38
Bone marrow examination in patients with Ewing sarcoma/peripheral primitive neuroectodermal tumor without metastasis based on 18F-fluorodeoxyglucose positron emission tomography/computed tomography. ( 31104192 )
2019
39
PET-CT imaging features that differentiate between positive and negative EWSR1 translocation in Ewing sarcoma. ( 31107830 )
2019
40
Five rare cases of Ewing sarcoma, including with epithelial differentiation, involving the female genital tract, displaying EWSR1 rearrangement: Diagnostic challenge and treatment implications. ( 31108450 )
2019
41
A case of Ewing sarcoma family tumor of the kidney treated with robotic-assisted partial nephrectomy. ( 31110948 )
2019
42
Chemokine Expression Is Involved in the Vascular Neogenesis of Ewing Sarcoma: A Preliminary Analysis of the Early Stages of Angiogenesis in a Xenograft Model. ( 29895220 )
2019
43
Ewing Sarcoma Presenting as a Congenital Scalp Mass. ( 29989837 )
2019
44
Adamantinoma-like Ewing Sarcoma of the Salivary Glands: A Newly Recognized Mimicker of Basaloid Salivary Carcinomas. ( 30285997 )
2019
45
A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma. ( 30397176 )
2019
46
Intracranial Ewing sarcoma with whole genome study. ( 30406421 )
2019
47
Early recognition and diagnosis of Ewing sarcoma of the cervical spine. ( 30416636 )
2019
48
Preclinical Efficacy of Endoglin-Targeting Antibody-Drug Conjugates for the Treatment of Ewing Sarcoma. ( 30420447 )
2019
49
Treatment and outcome of patients with thoracic tumors of the Ewing sarcoma family: A report from the Cooperative Weichteilsarkom Studiengruppe CWS-81, -86, -91, -96, and -2002P trials. ( 30421578 )
2019
50
MiR-708-5p is inversely associated with EWS/FLI1 Ewing sarcoma but does not represent a prognostic predictor. ( 30470587 )
2019

Variations for Ewing Sarcoma

ClinVar genetic disease variations for Ewing Sarcoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 TSC1 NM_000368.4(TSC1): c.1460C> G (p.Ser487Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs118203532 GRCh37 Chromosome 9, 135781505: 135781505
2 TSC1 NM_000368.4(TSC1): c.1460C> G (p.Ser487Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs118203532 GRCh38 Chromosome 9, 132906118: 132906118
3 CDK4 NM_000075.3(CDK4): c.776C> T (p.Ser259Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs201617914 GRCh37 Chromosome 12, 58143008: 58143008
4 CDK4 NM_000075.3(CDK4): c.776C> T (p.Ser259Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs201617914 GRCh38 Chromosome 12, 57749225: 57749225
5 BAP1 NM_004656.3(BAP1): c.256-3C> A single nucleotide variant Conflicting interpretations of pathogenicity rs752536342 GRCh37 Chromosome 3, 52442096: 52442096
6 BAP1 NM_004656.3(BAP1): c.256-3C> A single nucleotide variant Conflicting interpretations of pathogenicity rs752536342 GRCh38 Chromosome 3, 52408080: 52408080

Cosmic variations for Ewing Sarcoma:

9 (show all 46)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM43687 TP53 soft tissue,upper leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 0
2 COSM11333 TP53 soft tissue,upper leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 0
3 COSM6979022 SRC soft tissue,lung,sarcoma,NS c.205T>G p.S69A 20:37384358-37384358 0
4 COSM4774989 SH2B3 soft tissue,upper leg,sarcoma,NS c.232G>A p.E78K 12:111418377-111418377 0
5 COSM389868 RAC1 soft tissue,lung,sarcoma,NS c.476C>T p.A159V 7:6402343-6402343 0
6 COSM6979014 PTPRD soft tissue,lung,sarcoma,NS c.4160C>T p.A1387V 9:8404587-8404587 0
7 COSM6959031 PTCH1 soft tissue,lung,sarcoma,NS c.2921T>G p.F974C 9:95458260-95458260 0
8 COSM6979006 PBRM1 soft tissue,lung,sarcoma,NS c.2834G>A p.R945H 3:52589201-52589201 0
9 COSM6979021 PAK5 soft tissue,lung,sarcoma,NS c.41C>A p.P14Q 20:9644288-9644288 0
10 COSM6954536 NUP93 soft tissue,upper leg,sarcoma,NS c.116C>T p.A39V 16:56748363-56748363 0
11 COSM520 KRAS soft tissue,lung,sarcoma,NS c.35G>T p.G12V 12:25245350-25245350 0
12 COSM516 KRAS soft tissue,lung,sarcoma,NS c.34G>T p.G12C 12:25245351-25245351 0
13 COSM6979011 HGF soft tissue,lung,sarcoma,NS c.1711G>T p.V571L 7:81706333-81706333 0
14 COSM1732355 H3F3A soft tissue,bone,sarcoma,NS c.103G>T p.G35W 1:226064454-226064454 0
15 COSM6959034 GPS2 soft tissue,lung,sarcoma,NS c.454C>T p.Q152* 17:7313932-7313932 0
16 COSM3908208 GNAQ soft tissue,bone,sarcoma,NS c.442C>T p.R148* 9:77815650-77815650 0
17 COSM6979008 FOXP1 soft tissue,lung,sarcoma,NS c.74A>G p.H25R 3:71198308-71198308 0
18 COSM2923082 ANKRD11 soft tissue,upper leg,sarcoma,NS c.2882G>T p.R961L 16:89283660-89283660 0
19 COSM3908209 soft tissue,bone,sarcoma,NS c.355C>T p.R119* 9:77815650-77815650 0
20 COSM6959030 soft tissue,lung,sarcoma,NS c.2921T>G p.F974C 9:95458260-95458260 0
21 COSM1640840 soft tissue,upper leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 0
22 COSM307279 soft tissue,upper leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 0
23 COSM6979007 soft tissue,lung,sarcoma,NS c.2834G>A p.R945H 3:52589201-52589201 0
24 COSM6979005 soft tissue,lung,sarcoma,NS c.2738G>A p.R913H 3:52589201-52589201 0
25 COSM2744872 soft tissue,upper leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 0
26 COSM6979015 soft tissue,lung,sarcoma,NS c.2939C>T p.A980V 9:8404587-8404587 0
27 COSM6979012 soft tissue,lung,sarcoma,NS c.4160C>T p.A1387V 9:8404587-8404587 0
28 COSM1140136 soft tissue,lung,sarcoma,NS c.34G>T p.G12C 12:25245351-25245351 0
29 COSM6979020 soft tissue,lung,sarcoma,NS c.1831+1G>T p.? 19:45353082-45353082 0
30 COSM6979017 soft tissue,lung,sarcoma,NS c.2573C>T p.A858V 9:8404587-8404587 0
31 COSM6979010 soft tissue,lung,sarcoma,NS c.1036G>T p.V346L 3:179203766-179203766 0
32 COSM6979009 soft tissue,lung,sarcoma,NS c.74A>G p.H25R 3:71198308-71198308 0
33 COSM3937613 soft tissue,upper leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 0
34 COSM1154840 soft tissue,lung,sarcoma,NS c.533C>T p.A178V 7:6402343-6402343 0
35 COSM307282 soft tissue,upper leg,sarcoma,NS c.362A>G p.H121R 17:7674890-7674890 0
36 COSM6959033 soft tissue,lung,sarcoma,NS c.2918T>G p.F973C 9:95458260-95458260 0
37 COSM121082 soft tissue,upper leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 0
38 COSM121084 soft tissue,upper leg,sarcoma,NS c.103C>T p.Q35* 17:7675113-7675113 0
39 COSM121083 soft tissue,upper leg,sarcoma,NS c.220C>T p.Q74* 17:7675113-7675113 0
40 COSM3388198 soft tissue,upper leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 0
41 COSM6979016 soft tissue,lung,sarcoma,NS c.2930C>T p.A977V 9:8404587-8404587 0
42 COSM121081 soft tissue,upper leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 0
43 COSM307280 soft tissue,upper leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 0
44 COSM6979013 soft tissue,lung,sarcoma,NS c.2942C>T p.A981V 9:8404587-8404587 0
45 COSM6959032 soft tissue,lung,sarcoma,NS c.2918T>G p.F973C 9:95458260-95458260 0
46 COSM307281 soft tissue,upper leg,sarcoma,NS c.245A>G p.H82R 17:7674890-7674890 0

Copy number variations for Ewing Sarcoma from CNVD:

7 (show top 50) (show all 157)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13324 1 1 124300000 Deletion Ewing''s sarcoma
2 13741 1 1 27800000 Deletion Ewing''s sarcoma
3 16432 1 124300000 247249719 Gain Ewing''s sarcoma
4 16433 1 124300000 247249719 Gain Ewing''s sarcoma
5 16640 1 1286916 1536363 Loss Ewing''s sarcoma
6 17338 1 142400000 247249719 Gain Ewing''s sarcoma
7 17361 1 142565191 158296814 Gain AG1 Ewing''s sarcoma
8 20077 1 15300000 154800000 Gain Ewing''s sarcoma
9 20877 1 154978607 154979115 Gain HDGF Ewing''s sarcoma
10 21389 1 158408551 189951958 Gain FREB Ewing''s sarcoma
11 27410 1 208096981 208097464 Gain C1orf107 Ewing''s sarcoma
12 27922 1 215848737 215849264 Copy number GPATCH2 Ewing''s sarcoma
13 28256 1 220611046 220683633 Loss FBXO28 Ewing''s sarcoma
14 28623 1 224110806 224111244 Gain TMEM63A Ewing''s sarcoma
15 29204 1 228895774 228896323 Gain COG2 Ewing''s sarcoma
16 29247 1 229426179 229426672 Copy number C1orf131 Ewing''s sarcoma
17 29294 1 2300000 27800000 Deletion Ewing''s sarcoma
18 29735 1 234815741 234816376 Gain HEATR1 Ewing''s sarcoma
19 31804 1 3118000 5001000 Deletion Ewing''s sarcoma
20 31805 1 3118000 5001000 Deletion Ewing''s sarcoma
21 34220 1 53642491 53911866 Loss DMRTB1 Ewing''s sarcoma
22 35775 1 67181498 104009233 Loss SLC35D1 Ewing''s sarcoma
23 37996 1 9778925 10706826 Deletion APITD1 Ewing''s sarcoma
24 37997 1 9778925 10706826 Deletion CLSTN1 Ewing''s sarcoma
25 37998 1 9778925 10706826 Deletion CORT Ewing''s sarcoma
26 37999 1 9778925 10706826 Deletion CTNNBIP1 Ewing''s sarcoma
27 38000 1 9778925 10706826 Deletion DFFA Ewing''s sarcoma
28 38001 1 9778925 10706826 Deletion LZIC Ewing''s sarcoma
29 38002 1 9778925 10706826 Deletion NMNAT1 Ewing''s sarcoma
30 38003 1 9778925 10706826 Deletion PEX14 Ewing''s sarcoma
31 38004 1 9778925 10706826 Deletion PGD Ewing''s sarcoma
32 38005 1 9778925 10706826 Deletion RBP7 Ewing''s sarcoma
33 38141 10 1 135374737 Deletion Ewing''s sarcoma
34 41153 10 138206 135293404 Gain Ewing''s sarcoma
35 48491 11 1 52900000 Gain Ewing''s sarcoma
36 55430 11 52900000 134452384 Gain Ewing''s sarcoma
37 59789 11 777331 821974 Loss BM88 Ewing''s sarcoma
38 60445 11 86456481 127953177 Loss Ewing''s sarcoma
39 61420 12 1 132349534 Gain Ewing''s sarcoma
40 61533 12 1 35400000 Gain Ewing''s sarcoma
41 62737 12 111075038 111075556 Gain TRAFD1 Ewing''s sarcoma
42 63302 12 116955326 116955682 Copy number WSB2 Ewing''s sarcoma
43 64487 12 12873623 12874134 Gain DDX47 Ewing''s sarcoma
44 65323 12 1570852 1571348 Copy number FBXL14 Ewing''s sarcoma
45 66228 12 2670999 2671234 Deletion CACNA1C Ewing''s sarcoma
46 67041 12 35400000 132349534 Gain Ewing''s sarcoma
47 67472 12 41121456 41121979 Gain PPHLN1 Ewing''s sarcoma
48 68463 12 49967 52715434 Gain IQSEC3 Ewing''s sarcoma
49 68787 12 51501640 51502010 Copy number KRT79 Ewing''s sarcoma
50 69068 12 52981304 57130106 Gain Ewing''s sarcoma

Expression for Ewing Sarcoma

Search GEO for disease gene expression data for Ewing Sarcoma.

Pathways for Ewing Sarcoma

Pathways related to Ewing Sarcoma according to KEGG:

38
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

GO Terms for Ewing Sarcoma

Biological processes related to Ewing Sarcoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.91 ETV1 FLI1 MYC MYCN MYOG WT1
2 regulation of transcription by RNA polymerase II GO:0006357 9.86 ERG ETV1 ETV4 FLI1 KIT MYC
3 positive regulation of gene expression GO:0010628 9.85 KIT MYC MYCN POU5F1 WT1
4 positive regulation of transcription by RNA polymerase II GO:0045944 9.81 ERG ETV1 ETV4 FLI1 MYC MYCN
5 cell differentiation GO:0030154 9.8 ERG ETV1 ETV4 FLI1 MYOG
6 mRNA transcription by RNA polymerase II GO:0042789 9.49 MYOG POU5F1
7 megakaryocyte development GO:0035855 9.48 FLI1 KIT
8 positive regulation of DNA methylation GO:1905643 9.37 MYC WT1
9 regulation of transcription, DNA-templated GO:0006355 9.36 ERG ETV1 ETV4 EWSR1 FLI1 FUS
10 positive regulation of oxidative phosphorylation GO:1903862 9.32 MYC MYOG
11 transcription by RNA polymerase II GO:0006366 9.13 ETV1 MYC POU5F1

Molecular functions related to Ewing Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.91 ERG ETV1 ETV4 FLI1 MYC MYCN
2 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.7 ERG ETV1 ETV4 FLI1 MYC MYCN
3 sequence-specific DNA binding GO:0043565 9.56 ERG ETV1 ETV4 FLI1 MYC MYOG
4 DNA-binding transcription factor activity GO:0003700 9.28 ERG ETV1 ETV4 FLI1 MYC MYCN
5 protein binding GO:0005515 10.28 CD99 ENO2 ERG ETV1 ETV4 EWSR1
6 DNA binding GO:0003677 10.07 ERG ETV1 ETV4 FLI1 FUS MYC

Sources for Ewing Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....